Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder. The
available therapy is limited to the symptomatic treatment and its efficacy remains …

The molecular hybridization approach has been used to develop compounds with improved
efficacy by combining two or more pharmacophores of bioactive scaffolds. In this context …

During the research and development of new drugs directed at the central nervous system,
there is a considerable attrition rate caused by their hampered access to the brain by the …

By using fragments endowed with interesting and complementary properties for the
treatment of Alzheimer's disease (AD), a new family of tacrine–4-oxo-4 H-chromene hybrids …

The lack of an adequate therapy for Alzheimer's Disease (AD) contributes greatly to the
continuous growing amount of papers and reviews, reflecting the important efforts made by …

The formation of neurofibrillary tangles (NFTs), oxidative stress and neuroinflammation have
emerged as key targets for the treatment of Alzheimer's disease (AD), the most prevalent …

Due to the role of butyrylcholinesterase (BChE) in acetylcholine hydrolysis in the late stages
of the Alzheimer's disease (AD), inhibitors of butyrylcholinesterase (BChE) have been …

At present, one of the most promising strategies to tackle the complex challenges posed by
Alzheimer's disease (AD) involves the development of novel multitarget-directed ligands …

Herein we describe the design, multicomponent synthesis, and biological, molecular
modeling and ADMET studies, as well as in vitro PAMPA‐blood–brain barrier (BBB) analysis …

The synthesis, pharmacological analysis and molecular modeling of the readily available
racemic tacrine analogs 21–30, bearing the 7-aryl-9, 10, 11, 12-tetrahydro-7H-benzo [7, 8] …